Page 5 - Evofem Bioscience News Today

/PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today commended the Health Resources and Services Administration (HRSA) and the U.S. Department of...

/PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) and Orion Biotechnology Canada Ltd. today announced that they have entered into a collaboration...

/PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that it has successfully extended the cumulative net sales covenant timing of its...

/PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it has entered into a definitive agreement with Keystone Capital Partners...

/PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it intends to offer and sell in an underwritten public offering, subject to market...

Evofem Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Update -- Net Revenues Increased 550% Compared to 2020 Fourth Quarter -- -- Over 5,000 Healthcare Providers have Prescribed Phexxi to Date -- -- Management to Host Conference Call Today, Thursday, May 6, 2021, at 4:30 p.m. ET -- News provided by Share this article Share this article SAN DIEGO, May 6, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported fin...

Evofem Biosciences Announces Presentation of Two New Phexxi Data Sets at the 2021 American College of Obstetricians and Gynecologists Annual Meeting News provided by Share this article Share this article SAN DIEGO, April 28, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that two new data sets from its Phase 3 AMPOWER trial evaluating ® (lactic acid, citric acid, potassium bitartrate) will be presented at the 2021 American College of Obstetricians and Gynecol...

Evofem Biosciences DTC Campaign "Get Phexxi" Delivers Strong Initial Impact - Over 2,400 Phexxi units dispensed in February 2021, up 30% from prior month - - Accelerating retail demand drove 73% increase in ex-factory sales month-over-month - - Ex-factory sales YTD 2021 through mid-March have exceeded FY 2020 levels - News provided by Share this article Share this article SAN DIEGO, March 17, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that "Get Phexxi," its...

Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention News provided by Share this article Share this article SAN DIEGO, March 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology (AJOG). This double-blinded, placebo-cont...

Evofem Biosciences Wins Business Intelligence Groups BIG Innovation Award 2021 Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi® News provided by Share this article Share this article SAN DIEGO, Jan. 12, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) has been named a winner of Business Intelligence Groups 2021 BIG Innovation Awards for outstanding innovation with first-in-...